Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Radcliffe Department of Medicine identify a faulty molecular brake that interferes with heart muscle’s ability to contract and relax

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the condition’s cardinal feature—an unusually thick heart muscle that contracts and relaxes abnormally — is fuelled by some glitch in the heart’s molecular machinery. Yet, the precise spark plug that ignites such disordered muscle movement has thus far remained unknown.

Now a new study in Science Translational Medicine has pinpointed a faulty molecular brake that fuels disease development and identified a candidate compound that restores heart muscle function in human and mouse cells.

Read more (Radcliffe Department of Medicine website)

Similar stories

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.

Study indicates reasons for decline in death rates from heart attacks

A new study involving Oxford Population Health researchers finds that both prevention and improved treatments have helped reduce deaths from heart attacks - but the relative importance of each varies by country, age and sex.

Review highlights impact of Long COVID on cardiovascular system

The wide-ranging effects of Long COVID and the associated issues for healthcare providers have been revealed in a new review of the major studies into the condition, which specifically highlights the impact of Long COVID on the cardiovascular system.

Commercial development of therapeutic anti-inflammatory peptide begins

An Oxford BHF CRE “Pump Priming” award to Professor Shoumo Bhattacharya and his research group led to a great return on investment with this exclusive licensing agreement for their innovative research.

London Marathon to fund De Val and Vieira Lab research as two of eight handpicked BHF projects

Two projects aimed at tackling heart failure led by Associate Professor Sarah De Val and Dr Joaquim Vieira are to be funded by the 2022 TCS London Marathon with the British Heart Foundation as its Charity of the Year. The BHF’s runners, who are raising £3 million in funding, will include De Val Lab postdoctoral researcher Dr Alice Neal.

Dr Qiang Zhang wins Society for Cardiovascular Magnetic Resonance Early Career Award 2022

Many congratulations to Dr Qiang Zhang, Oxford BHF CRE Transition Fellow, who has won a prestigious award for his work in developing a groundbreaking technology for detecting scar in the myocardium